Actually read the report. Adding tarceva to Nexavar did not do better than nexavar alone.
""The data from SEARCH showed that the addition of Tarceva to Nexavar did not provide additional benefit to patients with unresectable HCC," said Dr. Dimitris Voliotis, Vice President, Global Clinical Development Oncology, Bayer HealthCare. "The results of this trial confirm the efficacy and safety profile of Nexavar in the treatment of unresectable liver cancer."
This is unfortunate for patients, sadly and is negative news for tarceva made by Genentech and astellas, but it is not negative news for Bayer and Onyx.
Yeah. Im a little embarrassed at how my post comes across when i look at it. Its emphasis was to refute the basher below who was suggesting this was negative for onyx. It is certainly much more important to focus on the patients and hope something better comes along for them soon no matter what it does to a stock.